These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283 [TBL] [Abstract][Full Text] [Related]
3. [Imatinib therapy for patients with chronic myelogenous leukemia]. Usui N Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812 [TBL] [Abstract][Full Text] [Related]
4. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553 [TBL] [Abstract][Full Text] [Related]
12. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376 [TBL] [Abstract][Full Text] [Related]
13. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830 [TBL] [Abstract][Full Text] [Related]
14. [Recent progress in therapy for chronic myelogenous leukemia]. Urabe A Gan To Kagaku Ryoho; 1997 Jul; 24(9):1066-73. PubMed ID: 9239158 [TBL] [Abstract][Full Text] [Related]
15. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833 [TBL] [Abstract][Full Text] [Related]
16. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia]. Usui N Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317 [TBL] [Abstract][Full Text] [Related]
17. [Second hematologic response and disappearance of the ABL gene mutant clone by cessation of imatinib in a CML patient with resistance to imatinib]. Murase K; Matsunaga T; Takeuchi N; Fujimi A; Takimoto R; Terui T; Hirayama Y; Niitsu Y Rinsho Ketsueki; 2004 Sep; 45(9):1028-32. PubMed ID: 15510830 [TBL] [Abstract][Full Text] [Related]